Summary: Pediatric neoplasm with monoclonal proliferation of lymphoplasmacytoid lymphocytes and plasma cells is exceedingly rare and has essentially never been reported in immunocompetent children. Here, we report a previously healthy 13-year-old girl with a pharyngeal mass and enlarged cervical lymph nodes. The pharyngeal mass was composed of CD138 + , CD79a + , MUM-1 + , IgD + , CD20
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Summary: Pediatric neoplasm with monoclonal proliferation of lymphoplasmacytoid lymphocytes and plasma cells is exceedingly rare and has essentially never been reported in immunocompetent children. Here, we report a previously healthy 13-year-old girl with a pharyngeal mass and enlarged cervical lymph nodes. The pharyngeal mass was composed of CD138 + , CD79a + , MUM-1 + , IgD + , CD20
À , PAX-5 À , CD43 À , l-restricted monoclonal plasmacytoid, and plasma cells. Scattered CD20 + , PAX-5 + B cells were present in the background. The patient was treated as localized non-Hodgkin lymphoma (stage II) with cyclophosphamide, doxorubicin, vincristine, and prednisone and is in complete remission at 17 months from the last chemotherapy.
Key Words: immunocompetent children, neoplasm, lymphoplasmacytoid lymphocytes, plasma cells, immunoglobulin D positive AQ2 (J Pediatr Hematol Oncol 2015;00:000-000) P ediatric non-Hodgkin B-cell lymphoma mainly includes Burkitt lymphoma and diffuse large B-cell lymphoma. 1 Indolent B-cell lymphoma in children is uncommon and is mainly comprised of marginal zone lymphoma (MZL) and follicular lymphoma. 2, 3 Pediatric MZL, unlike MZL in the adult population, predominantly includes nodal MZL. 4, 5 Extranodal MZL in children has rarely been reported and involved sites include the gastrointestinal tract, skin, orbits, salivary glands, tonsils, adenoids, appendix, lung, breast, and thymus. [4] [5] [6] [7] [8] [9] Other types of pediatric non-Hodgkin B-cell lymphoma, such as lymphoplasmacytic lymphoma (LPL) and plasma cell neoplasm (PCN), are exceedingly rare. 6, [10] [11] [12] Here, we report a neoplasm composed of predominantly immunoglobulin (Ig)D-positive monoclonal plasmacytoid and plasma cells in an immunocompetent 13-year-old girl with pharyngeal mass and cervical lymphadenopathy.
CASE REPORT
A 13-year-old girl with a history of tonsillectomy at age 3 noticed an abnormal mass in her throat with occasional pain. Physical examination revealed a submucosal linear mass measuring 4Â 1 cm, located in right posterior oropharynx near the old tonsil fossa. An ENT physician at an outside institution performed an excisional biopsy of the mass. Upon pathology report from that institution she was referred to our tertiary care center [Indiana University Health (IUH)] for further evaluation. She had no fever, night sweats, or weight loss. Her past medical history was otherwise unremarkable. Her family medical history included cervical cancer in her maternal grandmother, thyroid cancers in the sister and niece of her maternal grandmother, and lymphoma (type unknown) in her paternal grandfather. There was no family history of immunodeficiency. A whole body computed tomography and positronemission tomography scan revealed enlarged, bilateral, hypermetabolic, level II cervical lymph nodes, abnormal fullness, and intense metabolic activity in the lymphoid tissue in the tongue base, oropharynx, and nasopharynx. There was no evidence of metastatic disease outside of the neck. Her blood analysis showed normal complete blood count (white blood cells 3 ) and differential (56% neutrophils, 33% lymphocytes, and 9% monocytes), normal liver/renal functions, normal lactate dehydrogenase (162 U/L, reference: 100 to 242 U/L), and normal uric acid (5.4 mg/ dL, reference: 2 to 7 mg/dL).
Review of the excisional biopsy at IUH revealed histologically unremarkable squamous mucosa overlying marked proliferation of predominantly plasmacytoid lymphocytes and plasma cells. There were few scattered and rare aggregates of small lymphocytes (Fig. 1A) . Few residual salivary glands and rare follicles with germinal centers were noted. Immunohistochemical stains (Figs. 1B-H) performed at IUH showed the great majority of cells to be positive for CD79a, CD138, VS38, MUM-1, IgD, l light chain, and negative for CD3, CD20, PAX-5, CD5, CD10, CD23, CD43, cyclin D1, SOX11, BCL-6, CD56, CD117, CD123, k light chain, IgG, IgA, IgM, and S-100. The proliferative index as revealed by Ki-67 stain was low (< 10%). There were few CD20 + and/or PAX-5 + B cells in the background. CD21 and CD23 stains revealed rare follicular dendritic cell meshworks. Viral stain for HHV8 and in situ hybridization for Epstein-Barr virus-encoded RNAs (EBER) were negative. Per pathology report from AmeriPath Indiana (Indianapolis, Indiana), flow cytometric analysis (FCA) revealed a low-viability (approximately 25%) sample with few polyclonal B cells and immunophenotypically unremarkable T cells (markers tested: CD3, CD4, CD5, CD7, CD8, CD10, CD19, CD20, CD23, CD38, CD45, CD56, FMC7, sKappa, and sLambda). No FCA for plasma cells was performed. Fluorescence in situ hybridization performed at IUH revealed no API/MALT1 fusion or copy number changes of AP1 and MALT1 genes. Molecular study with multiplex PCR AQ3 performed at IUH showed clonal Ig heavy chain g rearrangement (Fig. 2) . No cytogenetic/ karyotyping study was performed at either outside or our own institute. A descriptive diagnosis of monoclonal plasmacytoid and PCN, most compatible with extranodal MZL of mucosa-associated lymphoid tissue (MALT lymphoma) with plasmacytic differentiation was rendered. Subsequent bilateral bone marrow examinations performed at IUH revealed few scattered l-predominant plasmacytoid/plasma cells (supplemental Fig. 1 ) counts and their subsets were within normal reference range. Serum studies for hepatitis A, B, C, and HIV were all negative. There was no monoclonal protein by serum protein electrophoresis test.
The patient was treated as stage II non-Hodgkin lymphoma (NHL) per POG9219 protocol (https://members.childrensoncology group.org/prot/ProtInfo.asp?ProtocolNum = 9219&Disease = NHL). Her postchemotherapy computed tomography and positron-emission tomography scan performed 1 week after completing chemotherapy revealed resolution of previous disease. Since that time she has been followed clinically and is currently in complete remission at 17 months from her last chemotherapy.
DISCUSSION
Small B-cell lymphoma with plasmacytic differentiation is used to describe a neoplasm of small B cells, plasmacytoid lymphocytes, and plasma cells. The major differential diagnosis includes MZL with plasmacytic differentiation and LPL. 13 In the pediatric population, MZL has been rarely reported including MZL with plasmacytic differentiation. However, essentially all the reported MZL cases contained aggregates and sheets of CD20 + B cells. 3, 5 Pediatric MZL tends to be IgD-negative and presents with localized disease (stage I). 5 The lesion in our case involved the patient's oropharynx and cervical lymph nodes (stage II). Histologically, the lesion was composed of sheets of IgD-positive, l-restricted monoclonal plasmacytoid lymphocytes and/or plasma cells. There were rare follicles as indicated by CD21 and CD23 stains. CD20 and PAX-5 stains revealed few B cells. The B cells were shown to be polyclonal by FCA, although the viability of the sample was very low (approximately 25%). The few B cells in our case were CD43 À , although the B cells in the reported pediatric MZL tend to be CD43
+ . There were no background progressive transformed germinal centers as LPL is essentially an adult disease. 13 To our knowledge there were only 2 reported pediatric cases of LPL/ LPL-like lesions which were both associated with WiskottAldrich syndrome and were self-limited. 12,14 Our patient did not have any history of recurrent infections and workup for possible immunodeficiency was negative. Similarly, PCN is exceedingly rare in children and is by current World Health Organization definition a neoplasm secreting heavy chain class-switched Ig. 15 Morphologically, however, our case was most compatible with LPL or PCN. As pediatric LPL and PCN are either extremely rare or have not been widely accepted in literature, and LPL in adults is typically IgD-negative, we were hesitant to render a diagnosis of LPL or PCN for this lesion.
Plasmablastic lymphoma (PBL) is a diffuse proliferation of large neoplastic cells which morphologically resemble B immunoblasts, but with the immunophenotype of plasma cells. The tumor cells are positive for CD138, CD38, VS38c, MUM-1, CD79 (majority), and are negative or only weakly positive for CD45, CD20, and PAX-5. The Epstein-Barr virus study (EBER) is commonly positive. PBL is an aggressive lymphoma typically with a high proliferation fraction. Patients with PBL usually have advanced disease (stage III or IV) and die within the first year after diagnosis. 16 Although it is most commonly seen in HIV-positive individuals, PBL has been reported in immunocompetent individuals. However, almost all PBL reported in immunocompetent individuals is seen in adults, whereas pediatric PBL is reported only in HIV-positive children. 17 20 Our case instead showed predominantly IgD-positive, IgM-negative plasmacytoid, and plasma cells with both l chain restriction by immunohistochemical stains and clonality by PCR analysis.
Here, we reported a highly unusual case of clinically stage II neoplasm composed of predominantly IgD-positive, l-restricted monoclonal plasmacytoid, and plasma cells, morphologically most compatible with LPL or PCN, in a 13-year-old girl with no significant past medical history. The patient was treated per POG9219 protocol for localized NHL and remains in complete remission 17 months after her last chemotherapy. In patients with localized (stage I or II) NHL treated with POG9219, the 5-year event-free survival is 83.7%, with an overall survival of 96%. The standard followup includes complete blood count along with clinical history and physical examination. No imaging is necessary unless a relapse was suspected if the patient was in full remission at the end of therapy (https://members.childrensoncologygroup. org/prot/ProtInfo.asp?ProtocolNum = 9219&Disease = NHL). Could this case represent an authentic pediatric LPL or PCN, or just a MZL with extreme plasmacytic differentiation? In adults, the distinction between B-cell lymphoma with plasmacytic differentiation and PCN is critical as they require different treatment. In the pediatric population, MZL usually requires only local treatment with long-term follow-up. 5 For our patient, long-term clinical follow-up may be helpful in the differential diagnosis. Report of other similar cases may also help to answer this question.
